Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aims</jats:title><jats:p>Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with UC.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The Pubmed, Embase and Scopus databases were searched up to June 25, 2021 in order to identify studies reporting efficacy and safety data of filgotinib in patients with UC.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Data from a phase III study enrolling UC patients with moderate to severe disease show that filgotinib is effective with a reassuring safety profile. Filgotinib treatment is not associated with a greater risk of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, animal studies reported impaired spermatogenesis and histopathological effects on male reproductive organs, making it necessary to deepen this aspect in dedicated human studies.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Filgotinib is an effective and safe drug for treatment of both biologic-naive and biologic-experienced patients with moderate to severe UC and may soon be available.</jats:p></jats:sec>